Outcomes of treatment cessation afterswitching to subcutaneous vedolizumab treatment in inflammatory bowel diseases

Hasonló tételek

• Advanced treatment options of inflammatory bowel diseases after anti-TNF failure
  Szerző: Bacsur Péter
  Megjelent: (2025)
• Role of antispasmodics in the treatment of irritable bowel syndrome
  Szerző: Annaházi Anita, et al.
  Megjelent: (2014)
• Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease results from a multicentre cohort study /
  Szerző: Bacsur Péter, et al.
  Megjelent: (2022)
• A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
  Szerző: Farkas Klaudia, et al.
  Megjelent: (2018)
• Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab
  Szerző: Szemes Kata, et al.
  Megjelent: (2024)